ZBIO (Zenas BioPharma) GF Score: 12/100 (As of Jul. 18, 2026) — 40% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $29.49
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma GF Score?

Zenas BioPharma ZBIO +4.57% 12 GF Score is 12 as of Jul. 18, 2026, which is 40% below its 10-year median of 20.00. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Zenas BioPharma has the GF Score of 12, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Zenas BioPharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Zenas BioPharma  (NAS:ZBIO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Zenas BioPharma GF Score Related Terms

ZBIO vs AKTS, MLTX, FTRE: GF Score Comparison

For the Biotechnology subindustry, Zenas BioPharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's GF Score distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's GF Score falls into.


ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 12 mean?
Zenas BioPharma (ZBIO) has a GF Score of 12 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zenas BioPharma and its competitors. This is 40% below median its historical median of 20.00. Over the past decade, Zenas BioPharma's GF Score has ranged from 12.00 to 22.00.
Is Zenas BioPharma's GF Score too high?
Zenas BioPharma's current GF Score of 12 is 40% below median its 10-year median of 20.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 22.00. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's GF Score compare to AKTS and MLTX?
Zenas BioPharma's GF Score of 12 can be compared against companies in the Biotechnology industry. Historically, Zenas BioPharma's own GF Score has ranged from 12.00 to 22.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current GF Score is 12, which is 40% below median its own 10-year median of 20.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current GF Score of 12. The current GF Score is 12, which is 40% below median its 10-year median of 20.00. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current GF Score is 12 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.49
Price